Compare Recursion Pharmaceuticals Inc (RXRX) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs ProShares Ultra Gold ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $4 (market cap $2.31B), while ProShares Ultra Gold ETF trades at $46.5 (market cap $715.43M). The key difference: Recursion Pharmaceuticals Inc is far larger — about 3.2× ProShares Ultra Gold ETF's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, ProShares Ultra Gold ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and ProShares Ultra Gold ETF for 23 Days on average.
| RXRX | UGL | |
|---|---|---|
Market Cap | $2.31B | $715.43M |
Volume | 40,478,768 | 3,002,043 |
Sector | Health | Leveraged / Inverse |
52-Week High | $6.79 | $85.62 |
52-Week Low | $2.84 | $42.79 |
Typical Hold Time | 22 Days | 23 Days |
Enterprise Value | $1.83B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
UGL stock is trading at $44.43, down 3.29% over the past day amid a broader bearish technical signal. The stock faces selling pressure with moving averages and oscillators indicating a downtrend, while key support lies at $43. Recent news highlights gold's volatility driven by shifting Federal Reserve rate expectations and Treasury yield movements, impacting sentiment.
The outlook remains cautious with technical indicators signaling bearish momentum, though oversold conditions on the 12-day RSI may offer short-term relief. Risks include persistent macroeconomic headwinds from interest rates and dollar strength, while the lack of available fundamental data limits visibility on the company's financial health and valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
